Cancer risks in BRCA1 carriers: Time for the next generation of studies

Journal of the National Cancer Institute

Volumn 94, Issue 18, 2002, Pages 1344-1345

  Gruber, Stephen B ^a   Petersen, Gloria M ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; TAMOXIFEN;

BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CANCER SUSCEPTIBILITY; COLON CANCER; CONTROLLED STUDY; DATA ANALYSIS; EDITORIAL; EUROPE; FAMILY; FEMALE; GENETIC COUNSELING; GERM LINE; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; LUNG CANCER; MALE; MASTECTOMY; MELANOMA; MUTATION; NORTH AMERICA; OVARY CANCER; PANCREAS CANCER; PENETRANCE; PRIORITY JOURNAL; PROBABILITY; PROSTATE CANCER; RISK ASSESSMENT; SALPINGOOOPHORECTOMY; STOMACH CANCER; UTERUS CANCER;

EID: 0037130881     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/94.18.1344     Document Type: Editorial

References (8)

1. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
2. Hartmann LC, Schaid DJ, Woods JE, Crotty TP, Myers JL, Arnold PG, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999;340:77-84.
3. Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999;91:1475-9.
4. Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002;94:1365-72.
5. Thompson D, Easton DF. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002;94:1358-1365.
6. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994; 343:692-5.
7. Tonin P, Weber B, Offit K, Couch F, Rebbeck TR, Neuhausen S, et al. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 1996;2:1179-83.
8. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8.